BASICS
DESCRIPTION
- Acute bacterial abscess of a hair follicle (often Staphylococcus aureus)
- System(s) affected: skin/exocrine
- Synonym(s): boils
EPIDEMIOLOGY
Incidence
- Predominant age
- Adolescents and young adults
- Clusters have been reported in teenagers living in crowded quarters, within families, or in high school athletes.
- Predominant sex: male = female
Prevalence
Exact data are not available.
ETIOLOGY AND PATHOPHYSIOLOGY
- Infection spreads away from hair follicle into surrounding dermis.
- Pathogenic strain of S. aureus (usually); most cases in United States are now due to community-acquired methicillin-resistant S. aureus (CA-MRSA) whereas methicillin-sensitive S. aureus (MSSA) is most common elsewhere (1).
Genetics
Unknown
RISK FACTORS
- Carriage of pathogenic strain of Staphylococcus sp. in nares, skin, axilla, and perineum
- Rarely, polymorphonuclear leukocyte defect or hyperimmunoglobulin E-Staphylococcus sp. abscess syndrome
- Diabetes mellitus, malnutrition, alcoholism, obesity, atopic dermatitis
- Primary immunodeficiency disease and AIDS (common variable immunodeficiency, chronic granulomatous disease, Chediak-Higashi syndrome, C3 deficiency, C3 hypercatabolism, transient hypogammaglobulinemia of infancy, immunodeficiency with thymoma, Wiskott-Aldrich syndrome)
- Secondary immunodeficiency (e.g., leukemia, leukopenia, neutropenia, therapeutic immunosuppression)
- Medication impairing neutrophil function (e.g., omeprazole)
- The most important independent predictor of recurrence is a positive family history.
GENERAL PREVENTION
Patient education regarding self-care (see "General Measures"); treatment and prevention are interrelated.
COMMONLY ASSOCIATED CONDITIONS
- Usually normal immune system
- Diabetes mellitus
- Polymorphonuclear leukocyte defect (rare)
- Hyperimmunoglobulin E-Staphylococcus sp. abscess syndrome (rare)
- See "Risk Factors."
DIAGNOSIS
HISTORY
- Located on hair-bearing sites, especially areas prone to friction or repeated minor traumas (e.g., underneath belt, anterior aspects of thighs, nape, buttocks)
- No initial fever or systemic symptoms
- The folliculocentric nodule may enlarge, become painful, and develop into an abscess (frequently with spontaneous drainage).
PHYSICAL EXAM
- Painful erythematous papules/nodules (1 to 5 cm) with central pustules
- Tender, red, perifollicular swelling, terminating in discharge of pus and necrotic plug
- Lesions may be solitary or clustered.
DIFFERENTIAL DIAGNOSIS
- Folliculitis
- Pseudofolliculitis
- Carbuncles
- Ruptured epidermal cyst
- Myiasis (larva of botfly/tumbu fly)
- Hidradenitis suppurativa
- Atypical bacterial or fungal infections
DIAGNOSTIC TESTS & INTERPRETATION
Initial Tests (lab, imaging)
Obtain culture if with multiple abscesses marked by surrounding inflammation, cellulitis, systemic symptoms such as fever, or if immunocompromised.
Follow-Up Tests & Special Considerations
- Immunoglobulin levels in rare (e.g., recurrent or otherwise inexplicable) cases
- If culture grows gram-negative bacteria or fungus, consider polymorphonuclear neutrophil leukocyte functional defect.
Test Interpretation
Histopathology (although a biopsy is rarely needed)
- Perifollicular necrosis containing fibrinoid material and neutrophils
- At deep end of necrotic plug, in SC tissue, is a large abscess with a Gram stain positive for small collections of S. aureus.
TREATMENT
GENERAL MEASURES
- Moist, warm compresses (provide comfort, encourage localization/pointing/drainage) 30 minutes QID
- If pointing or large, incise and drain: consider packing if large or incompletely drained.
- Routine culture is not necessary for localized abscess in nondiabetic patients with normal immune system.
- Sanitary practices: change towels, washcloths, and sheets daily; clean shaving instruments; avoid nose picking; change wound dressings frequently; do not share items of personal hygiene (2)[B].
MEDICATION
First Line
- Systemic antibiotics usually unnecessary, unless extensive surrounding cellulitis or fever
- If suspecting MRSA, see "Second Line."
- If multiple abscesses, lesions with marked surrounding inflammation, cellulitis, systemic symptoms such as fever, or if immunocompromised: place on antibiotics therapy directed at S. aureus for 10 to 14 days.
- Dicloxacillin (Dynapen, Pathocil) 500 mg PO QID or cephalexin 500 mg PO QID or clindamycin 300 mg TID, if penicillin-allergic
Second Line
- Resistant strains of S. aureus (MRSA): clindamycin 300 mg q6h or doxycycline 100 mg q12h or trimethoprim-sulfamethoxazole (TMP-SMX DS) 1 tab q8-12h or minocycline 100 mg q12h
- If known or suspected impaired neutrophil function (e.g., impaired chemotaxis, phagocytosis, superoxide generation), add vitamin C 1,000 mg/day for 4 to 6 weeks (prevents oxidation of neutrophils).
- If antibiotic regimens fail:
- May try PO pentoxifylline 400 mg TID for 2 to 6 months
- Contraindications: recent cerebral and/or retinal hemorrhage; intolerance to methylxanthines (e.g., caffeine, theophylline); allergy to the particular drug selected
- Precautions: prolonged prothrombin time (PT) and/or bleeding; if on warfarin, frequent monitoring of PT
ONGOING CARE
FOLLOW-UP RECOMMENDATIONS
Patient Monitoring
Instruct patient to see physician if compresses are unsuccessful.
DIET
Unrestricted
PROGNOSIS
- Self-limited: usually drains pus spontaneously and will heal with or without scarring within several days.
- Recurrent/chronic: may last for months or years
- If recurrent, usually related to chronic skin carriage of staphylococci (nares or on skin). Treatment goals are to decrease or eliminate pathogenic strain or suppress pathogenic strain.
- Culture nares, skin, axilla, and perineum (culture nares of family members).
- Mupirocin 2%: Apply to both nares BID for 5 days each month.
- Culture anterior nares every 3 months; if failure, retreat with mupirocin or consider clindamycin 150 mg/day for 3 months.
- Especially in recurrent cases, wash entire body and fingernails (with nailbrush) daily for 1 to 3 weeks with povidone-iodine (Betadine), chlorhexidine (Hibiclens), or hexachlorophene (pHisoHex soap), although all can cause dry skin.
COMPLICATIONS
- Scarring
- Bacteremia
- Seeding (e.g., septal/valve defect, arthritic joint)
REFERENCES
11 Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167(4):725-732.22 Fritz SA, Camins BC, Eisenstein KA, et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol. 2011; 32(9):872-880.
ADDITIONAL READING
- El-Gilany AH, Fathy H. Risk factors of recurrent furunculosis. Dermatol Online J. 2009;15(1):16.
- Ibler KS, Kromann CB. Recurrent furunculosis-challenges and management: a review. Clin Cosmet Investig Dermatol. 2014;7:59-64.
- McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy. 2009;29(3):263-280.
- Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc. 2011;86(12):1230-1243.
- Wahba-Yahav AV. Intractable chronic furunculosis: prevention of recurrences with pentoxifylline. Acta Derm Venereol. 1992;72(6):461-462.
- Winthrop KL, Abrams M, Yakrus M, et al. An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon. N Engl J Med. 2002;346(18):1366-1371.
SEE ALSO
Folliculitis; Hidradenitis Suppurativa
CODES
ICD10
- L02.92 Furuncle, unspecified
- L02.12 Furuncle of neck
- L02.429 Furuncle of limb, unspecified
- L02.32 Furuncle of buttock
- L02.425 Furuncle of right lower limb
- L02.422 Furuncle of left axilla
- L02.426 Furuncle of left lower limb
- L02.621 Furuncle of right foot
- L02.424 Furuncle of left upper limb
- L02.423 Furuncle of right upper limb
- L02.229 Furuncle of trunk, unspecified
- L02.222 Furuncle of back [any part, except buttock]
- L02.02 Furuncle of face
- L02.629 Furuncle of unspecified foot
- L02.622 Furuncle of left foot
- L02.821 Furuncle of head [any part, except face]
- L02.221 Furuncle of abdominal wall
- L02.225 Furuncle of perineum
- L02.828 Furuncle of other sites
- L02.529 Furuncle unspecified hand
- L02.224 Furuncle of groin
- L02.226 Furuncle of umbilicus
- L02.421 Furuncle of right axilla
- L02.223 Furuncle of chest wall
- L02.522 Furuncle left hand
- L02.521 Furuncle right hand
ICD9
- 680.9 Carbuncle and furuncle of unspecified site
- 680.1 Carbuncle and furuncle of neck
- 680.3 Carbuncle and furuncle of upper arm and forearm
- 680.5 Carbuncle and furuncle of buttock
- 680.4 Carbuncle and furuncle of hand
- 680.8 Carbuncle and furuncle of other specified sites
- 680.0 Carbuncle and furuncle of face
- 680.2 Carbuncle and furuncle of trunk
- 680.6 Carbuncle and furuncle of leg, except foot
- 680.7 Carbuncle and furuncle of foot
SNOMED
- 40603000 Furunculosis of skin AND/OR subcutaneous tissue (disorder)
- 47763005 Furuncle of neck (disorder)
- 60198007 Furuncle of axilla
- 12430003 Furuncle of buttock (disorder)
- 37396007 Furuncle of face
- 67272008 Furuncle of trunk (disorder)
- 90942002 Furuncle of thigh
- 2606006 Furuncle of perineum
CLINICAL PEARLS
- Pathogens may be different in different localities. Keep up-to-date with the locality-specific epidemiology.
- If few, furuncles/furunculosis do not need antibiotic treatment. If systemic symptoms (e.g., fever), cellulitis, or multiple lesions occur, oral antibiotic therapy is used.
- Other treatments for MRSA include linezolid PO or IV and IV vancomycin.
- Folliculitis, furunculosis, and carbuncles are parts of a spectrum of pyodermas.
- Other causative organisms include aerobic (e.g., Escherichia coli, Pseudomonas aeruginosa, and Streptococcus faecalis), anaerobic (e.g., Bacteroides, Lactobacillus, Peptobacillius, and Peptostreptococcus), and Mycobacteria.
- Decolonization (treatment of the nares with topical antibiotic) is only recommended if the colonization was confirmed by cultures because resistance is common and treatment is of uncertain efficacy.